Skip to site menu Skip to page content

How to Choose the Right Solubilisation Technology for an API

By Patheon

The proportion of poorly soluble drug compounds in the development pipeline is on the rise, with 70% to 90% of current pipeline drugs falling in the two low-solubility classes of the biopharmaceutical classification system.

With the emergence of new techniques to improve solubility, low solubility compounds are more likely to advance to the clinic.

However, the large spectrum of available technologies can make it challenging for the formulation scientist to proceed in an informed and rational manner.

Download to find out more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content